ArticleClinical and translational medicine2015
Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer.
Article in Clinical and translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
158 citing papers in PubMed, 3 syntheses or guidelines pooled it, 264 citations in OpenAlex.
- Circulating Levels of Hydrogen Sulfide (HBiomolecules · 2023Pooled it
- Defining the role of neutrophil-to-lymphocyte ratio in COPD: a systematic literature review.International journal of chronic obstructive pulmonary diseasePooled it
- Risk of Coronary Heart Disease in People with Chronic Obstructive Pulmonary Disease: A Meta-Analysis.International journal of chronic obstructive pulmonary diseasePooled it
- Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials.Clinical and translational science · 2024Trial
- Association of Serum hs-CRP and TNF-α With Therapeutic Response to Erenumab for Migraine Prevention: A Registry for Migraine (REFORM) Study.European journal of neurology · 2026Observational
- Baseline Chronic Obstructive Pulmonary Disease Identifies a High-Risk Cardiopulmonary Phenotype in Patients with Heart Failure Undergoing SGLT2 Inhibitor Therapy.Diagnostics (Basel, Switzerland) · 2026Article
- Immune Roles of Canonically Non-Immune Cells in Biomaterials Response.Cell biomaterials · 2026Article
- Inherited genetic risk factors in young-onset lung cancer.medRxiv : the preprint server for health sciences · 2026Article
- Long-Term Outcomes After Percutaneous Coronary Intervention According to the High-Sensitivity C-Reactive Protein-to-Albumin Ratio in Patients With Chronic Obstructive Pulmonary Disease in China.Reviews in cardiovascular medicine · 2026Article
- Impact of ambient particulate matter and meteorological factors on COPD risk and its association with blood eosinophilia.BMC pulmonary medicine · 2026Article
- Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions.Cancer cell · 2026Article
- Common Biomarkers in Chronic Obstructive Pulmonary Disease and Bronchopulmonary Dysplasia: A Narrative Review of an Intriguing Interplay.International journal of molecular sciences · 2026Review
- Article
- Association between the Endothelial Activation and Stress Index and all-cause mortality in patients with chronic obstructive pulmonary disease.Frontiers in medicine · 2026Article
- Lung scRNA-seq reveals chronic inflammation and emphysemous phenotype in mice with osteogenesis imperfecta.Frontiers in genetics · 2026Article
- Association Between Chronic Obstructive Pulmonary Disease and Survival in Patients with Lung Cancer: A Nationwide Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
- SHAP-interpretable machine learning integrating exposures and multi-omics reveals immune alterations and biomarkers in COPD-lung cancer comorbidity.Frontiers in immunology · 2026Article
- COPD and Cardiovascular Diseases: Biomarker-Guided Stratification and Therapeutic Perspectives.Journal of clinical medicine · 2025Review
- Computational identification of key genetic drivers in COPD: A first step towards uncovering candidate biomarkers in smokers.Biochemistry and biophysics reports · 2025Article
- Inflammatory microenvironment-responsive MR imaging contrast agents.Nanomedicine (London, England) · 2025Review
98 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is characterized by lung inflammation that persists after smoking cessation. This inflammation is heterogeneous but the key inflammatory cell types involved are macrophages, neutrophils and T cells. Other lung cells may also produce inflammatory mediators, particularly the epithelial cells. The main inflammatory mediators include tumor necrosis factor alpha, interleukin-1, interleukin-6, reactive oxygen species and proteases. COPD is also associated with systemic inflammation and there is a markedly increased risk of cardiovascular disease (particularly coronary artery disease) and lung cancer in patients with COPD. There is strong associative evidence that the inflammatory cells/mediators in COPD are also relevant to the development of cardiovascular disease and lung cancer. There are a large number of potential inhibitors of inflammation in COPD that may well have beneficial effects for these comorbidities. This is a not well-understood area and there is a requirement for more definitive clinical and mechanistic studies to define the relationship between the inflammatory process of COPD and cardiovascular disease and lung cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.